This site is intended for Healthcare Professionals only

Colchicine may not lessen Covid-19 severity

News bookmark icon off

Colchicine may not lessen Covid-19 severity

Colchicine, an anti-inflammatory drug normally used to treat gout, doesn’t lessen Covid-19 severity or stave off the risk of death in hospital patients. It is also associated with a high risk of side effects, according to research published in RMD Open.

Early observational studies had suggested that colchicine might be a useful Covid-19 treatment, but the new research concludes: “Colchicine does not reduce the risk of mortality, need for ventilatory support, intensive care unit admission or length of hospital stay among patients with Covid-19.” 

The researchers do say, however, that their findings should be interpreted cautiously due to the inclusion of open labelled randomised clinical trial data. 

Copy Link Record my learning outcomes
Save for later bookmark icon off


Stay up to date with all the news, learning and insight in the world of pharmacy.